Efficacy of HIVEC in patients with high-risk non-muscle invasive bladder cancer who are contraindicated to BCG and in patients who fail BCG therapy

Purpose To evaluate Hyperthermic-Intra-Vesical Chemotherapy (HIVEC) efficacy regarding 1-year disease-free survival (RFS) rate and bladder preservation rate in patients with High-risk Non-Muscle Invasive Bladder Cancer (NMIBC) who fail BCG therapy or are contraindicated to BCG. Methods Between June...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Laure Doisy, Arnaud Cimier, Aurélien Adypagavane, Jochen Walz, Thibault Marquette, Thomas Maubon, Stanislas Rybikowski, Sami Fakhfakh, Kevin Loverde, Nicolas Mottet, Jacques Irani, Eric Lechevallier, Dominique Rossi, Gwenaelle Gravis, Géraldine Pignot
Formato:	article
Lenguaje:	EN
Publicado:	Taylor & Francis Group 2021
Materias:	bladder cancer bcg-refractory cystectomy chemohyperthermia recurrence progression Medical technology R855-855.5
Acceso en línea:	https://doaj.org/article/2244ac07f40049d88cd6f64b4d121df2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2244ac07f40049d88cd6f64b4d121df2
record_format	dspace
spelling	oai:doaj.org-article:2244ac07f40049d88cd6f64b4d121df22021-11-17T14:21:55ZEfficacy of HIVEC in patients with high-risk non-muscle invasive bladder cancer who are contraindicated to BCG and in patients who fail BCG therapy0265-67361464-515710.1080/02656736.2021.2002435https://doaj.org/article/2244ac07f40049d88cd6f64b4d121df22021-01-01T00:00:00Zhttp://dx.doi.org/10.1080/02656736.2021.2002435https://doaj.org/toc/0265-6736https://doaj.org/toc/1464-5157Purpose To evaluate Hyperthermic-Intra-Vesical Chemotherapy (HIVEC) efficacy regarding 1-year disease-free survival (RFS) rate and bladder preservation rate in patients with High-risk Non-Muscle Invasive Bladder Cancer (NMIBC) who fail BCG therapy or are contraindicated to BCG. Methods Between June 2016 and October 2019, patients treated with HIVEC for mostly high-risk NMIBC who failed BCG or BCG-naive if BCG contraindicated have been included in our study. These patients had a theoretical indication for cystectomy but were ineligible for surgery or refused it. Results Fifty-three patients, median age 72 [39–93] years, were included in this study (n = 29 BCG-failure and n = 24 BCG-naive). The median follow-up was 18 months. The bladder preservation rate was 92.4%. The 12 months-RFS rate was 60.5%. The RFS rates for BCG-naive and BCG-failure groups were respectively 70% and 52.2% at 12 months. Three patients progressed to muscle infiltration, all in the BCG-failure group and all in the very high-risk EORTC group. Two of them developed metastatic disease and died from bladder cancer. Conclusion Chemohyperthermia using HIVEC achieved a RFS rate of 60% at 1 year and enabled a bladder preservation rate of 92%. Given the low risk of progression in the BCG-naive group, HIVEC could be a good alternative. Conversely, for patients with very high-risk tumors that fail BCG, cystectomy should remain the standard of care and HIVEC may be discussed cautiously for patients who are not eligible for surgery and well informed of the risk of progression to muscle-invasive disease.Laure DoisyArnaud CimierAurélien AdypagavaneJochen WalzThibault MarquetteThomas MaubonStanislas RybikowskiSami FakhfakhKevin LoverdeNicolas MottetJacques IraniEric LechevallierDominique RossiGwenaelle GravisGéraldine PignotTaylor & Francis Grouparticlebladder cancerbcg-refractorycystectomychemohyperthermiarecurrenceprogressionMedical technologyR855-855.5ENInternational Journal of Hyperthermia, Vol 38, Iss 1, Pp 1633-1638 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	bladder cancer bcg-refractory cystectomy chemohyperthermia recurrence progression Medical technology R855-855.5
spellingShingle	bladder cancer bcg-refractory cystectomy chemohyperthermia recurrence progression Medical technology R855-855.5 Laure Doisy Arnaud Cimier Aurélien Adypagavane Jochen Walz Thibault Marquette Thomas Maubon Stanislas Rybikowski Sami Fakhfakh Kevin Loverde Nicolas Mottet Jacques Irani Eric Lechevallier Dominique Rossi Gwenaelle Gravis Géraldine Pignot Efficacy of HIVEC in patients with high-risk non-muscle invasive bladder cancer who are contraindicated to BCG and in patients who fail BCG therapy
description	Purpose To evaluate Hyperthermic-Intra-Vesical Chemotherapy (HIVEC) efficacy regarding 1-year disease-free survival (RFS) rate and bladder preservation rate in patients with High-risk Non-Muscle Invasive Bladder Cancer (NMIBC) who fail BCG therapy or are contraindicated to BCG. Methods Between June 2016 and October 2019, patients treated with HIVEC for mostly high-risk NMIBC who failed BCG or BCG-naive if BCG contraindicated have been included in our study. These patients had a theoretical indication for cystectomy but were ineligible for surgery or refused it. Results Fifty-three patients, median age 72 [39–93] years, were included in this study (n = 29 BCG-failure and n = 24 BCG-naive). The median follow-up was 18 months. The bladder preservation rate was 92.4%. The 12 months-RFS rate was 60.5%. The RFS rates for BCG-naive and BCG-failure groups were respectively 70% and 52.2% at 12 months. Three patients progressed to muscle infiltration, all in the BCG-failure group and all in the very high-risk EORTC group. Two of them developed metastatic disease and died from bladder cancer. Conclusion Chemohyperthermia using HIVEC achieved a RFS rate of 60% at 1 year and enabled a bladder preservation rate of 92%. Given the low risk of progression in the BCG-naive group, HIVEC could be a good alternative. Conversely, for patients with very high-risk tumors that fail BCG, cystectomy should remain the standard of care and HIVEC may be discussed cautiously for patients who are not eligible for surgery and well informed of the risk of progression to muscle-invasive disease.
format	article
author	Laure Doisy Arnaud Cimier Aurélien Adypagavane Jochen Walz Thibault Marquette Thomas Maubon Stanislas Rybikowski Sami Fakhfakh Kevin Loverde Nicolas Mottet Jacques Irani Eric Lechevallier Dominique Rossi Gwenaelle Gravis Géraldine Pignot
author_facet	Laure Doisy Arnaud Cimier Aurélien Adypagavane Jochen Walz Thibault Marquette Thomas Maubon Stanislas Rybikowski Sami Fakhfakh Kevin Loverde Nicolas Mottet Jacques Irani Eric Lechevallier Dominique Rossi Gwenaelle Gravis Géraldine Pignot
author_sort	Laure Doisy
title	Efficacy of HIVEC in patients with high-risk non-muscle invasive bladder cancer who are contraindicated to BCG and in patients who fail BCG therapy
title_short	Efficacy of HIVEC in patients with high-risk non-muscle invasive bladder cancer who are contraindicated to BCG and in patients who fail BCG therapy
title_full	Efficacy of HIVEC in patients with high-risk non-muscle invasive bladder cancer who are contraindicated to BCG and in patients who fail BCG therapy
title_fullStr	Efficacy of HIVEC in patients with high-risk non-muscle invasive bladder cancer who are contraindicated to BCG and in patients who fail BCG therapy
title_full_unstemmed	Efficacy of HIVEC in patients with high-risk non-muscle invasive bladder cancer who are contraindicated to BCG and in patients who fail BCG therapy
title_sort	efficacy of hivec in patients with high-risk non-muscle invasive bladder cancer who are contraindicated to bcg and in patients who fail bcg therapy
publisher	Taylor & Francis Group
publishDate	2021
url	https://doaj.org/article/2244ac07f40049d88cd6f64b4d121df2
work_keys_str_mv	AT lauredoisy efficacyofhivecinpatientswithhighrisknonmuscleinvasivebladdercancerwhoarecontraindicatedtobcgandinpatientswhofailbcgtherapy AT arnaudcimier efficacyofhivecinpatientswithhighrisknonmuscleinvasivebladdercancerwhoarecontraindicatedtobcgandinpatientswhofailbcgtherapy AT aurelienadypagavane efficacyofhivecinpatientswithhighrisknonmuscleinvasivebladdercancerwhoarecontraindicatedtobcgandinpatientswhofailbcgtherapy AT jochenwalz efficacyofhivecinpatientswithhighrisknonmuscleinvasivebladdercancerwhoarecontraindicatedtobcgandinpatientswhofailbcgtherapy AT thibaultmarquette efficacyofhivecinpatientswithhighrisknonmuscleinvasivebladdercancerwhoarecontraindicatedtobcgandinpatientswhofailbcgtherapy AT thomasmaubon efficacyofhivecinpatientswithhighrisknonmuscleinvasivebladdercancerwhoarecontraindicatedtobcgandinpatientswhofailbcgtherapy AT stanislasrybikowski efficacyofhivecinpatientswithhighrisknonmuscleinvasivebladdercancerwhoarecontraindicatedtobcgandinpatientswhofailbcgtherapy AT samifakhfakh efficacyofhivecinpatientswithhighrisknonmuscleinvasivebladdercancerwhoarecontraindicatedtobcgandinpatientswhofailbcgtherapy AT kevinloverde efficacyofhivecinpatientswithhighrisknonmuscleinvasivebladdercancerwhoarecontraindicatedtobcgandinpatientswhofailbcgtherapy AT nicolasmottet efficacyofhivecinpatientswithhighrisknonmuscleinvasivebladdercancerwhoarecontraindicatedtobcgandinpatientswhofailbcgtherapy AT jacquesirani efficacyofhivecinpatientswithhighrisknonmuscleinvasivebladdercancerwhoarecontraindicatedtobcgandinpatientswhofailbcgtherapy AT ericlechevallier efficacyofhivecinpatientswithhighrisknonmuscleinvasivebladdercancerwhoarecontraindicatedtobcgandinpatientswhofailbcgtherapy AT dominiquerossi efficacyofhivecinpatientswithhighrisknonmuscleinvasivebladdercancerwhoarecontraindicatedtobcgandinpatientswhofailbcgtherapy AT gwenaellegravis efficacyofhivecinpatientswithhighrisknonmuscleinvasivebladdercancerwhoarecontraindicatedtobcgandinpatientswhofailbcgtherapy AT geraldinepignot efficacyofhivecinpatientswithhighrisknonmuscleinvasivebladdercancerwhoarecontraindicatedtobcgandinpatientswhofailbcgtherapy
_version_	1718425469084237824

Efficacy of HIVEC in patients with high-risk non-muscle invasive bladder cancer who are contraindicated to BCG and in patients who fail BCG therapy

Ejemplares similares